glp-1 receptor agonist agent Agonists as Treatments for Type 2 Diabetes Evolution of GLP‐1 Receptor Agonists

High-throughput screening campaigns against the GLP-1 receptor and other class B GPCRs consistently yielded low hit rates for small molecules, and the few hits that emerged typically showed micromolar potency, insufficient for therapeutic applications

There is a pressing need to expand clinical trial evidence to solidify their therapeutic role in non-diabetic populations for primary prevention and for specific conditions, such as vascular dementia

Page, M

By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free